Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2018

View Archived Issues

Aduro earns milestone from Merck & Co. for initiation of phase I trial of anti-CD27 antibody

Caladrius Biosciences acquires license to late-stage CD34+ cell therapy program from Shire

Eisai and Purdue Pharma report results from clinical studies of lemborexant

Pivotal phase III study of bempedoic acid in ASCVD meets primary endpoint

Vocimagene amiretrorepvec/5-fluorocytosine granted E.U. orphan designation for glioma

Researchers evaluate safety and immunogenicity of a new anti-allergic vaccine

MD Anderson Cancer Center and Berkeley Lights launch new company

Phase IIb study of BTK inhibitor in MS meets primary endpoint

Oxford Vacmedix closes series A funding to develop its two lead cancer vaccine candidates

NTP-42 receives E.U., U.S. orphan designations for pulmonary arterial hypertension

Compugen licenses SUREtechnology platform from Selexis

Antimicrobial polymers show killing activity without leading to resistance

University of Bristol presents new alpha4beta2 nicotinic receptor partial agonists

Novel NF-kappaB inhibitors synthesized at University College Dublin

Arena Pharmaceuticals patents new 5-HT2C receptor agonists

Genoimmune Therapeutics creates novel human leukocyte antigen-binding polypeptides

New polynucleotides encoding semaphorin-6 synthesized at Kanazawa University

Evotec and Sanofi in negotiations over new open innovation platform in infectious disease

Eisai and Merck & Co. agree on strategic collaboration for Lenvima

Harbin Medical University presents data on PET tracer for EGFR mutation determination

Immuron announces topline phase II results for IMM-124E in NASH

MuSK stimulation preserves neuromuscular synapses in amyotrophic lateral sclerosis

Medicure to commercialize Zydus Cadila's pitavastatin in U.S.

Daiichi Sankyo initiates phase II study of DS-8201 in HER2-expressing colorectal cancer

Aevi Genomic Medicine and Kyowa Hakko Kirin expand collaboration